Document is current
Any future updates will be listed below
-
Authors
Paradise, Victoria https://orcid.org/0009-0000-9687-1422
Konrad-Vicario, Kalin D.
Nguyen, Chi https://orcid.org/0000-0003-3100-3506
Sharif, Nyle A. https://orcid.org/0000-0003-2412-3286
Wang, Xiao https://orcid.org/0000-0001-7406-0346
Mukim, Rijuta D.
Sabu, Malavika
Corjuc, Bianca T.
Bafia, Joanna
Fu, Jack
Maldonado, Gabriella C. https://orcid.org/0009-0007-2277-3070
Strickland, Michael https://orcid.org/0000-0002-3899-5651
Grauman, Sarah L.
Figueroa, Helen
Hyman, Bradley T. https://orcid.org/0000-0002-7959-9401
Holtzman, David M. https://orcid.org/0000-0002-3400-0856
Nuriel, Tal https://orcid.org/0000-0002-5252-8048
Ramachandran, Kapil V. https://orcid.org/0000-0002-4944-3553
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (7DP5OD028133)
U.S. Department of Health & Human Services | National Institutes of Health (P30AG062421)
U.S. Department of Health & Human Services | National Institutes of Health (RF1AG047644)
U.S. Department of Health & Human Services | National Institutes of Health (R01NS090934)
U.S. Department of Health & Human Services | National Institutes of Health (U19AG069701)
U.S. Department of Defense (W81ZWH-21-1-0093)
Cure Alzheimer's Fund
Alzheimer's Association (AARFD-23-1151195)
Esther A. and Joseph Klingenstein Fund
Columbia University
Eli Lilly and Company
National Science Foundation (2024369596)
NSF | Directorate for Biological Sciences (2024369596)
- License Information
-
More Information
Article History
Received: 1 January 2025
Accepted: 6 April 2026
First Online: 29 May 2026
Competing interests
: K.V.R. is an inventor on a patent on the cell-impermeable proteasome inhibitors described here. K.V.R. received funding from Eli Lilly and Company. D.M.H. is an inventor on a patent licensed by Washington University to NextCure on the therapeutic use of anti-apoE antibodies. D.M.H. cofounded, has equity in and is on the scientific advisory board of C2N Diagnostics. D.M.H. is on the scientific advisory boards of Denali, Genentech, Acta and Cajal Neuroscience and consults for Pfizer, Roche and Switch Therapeutics. The remaining authors declare no competing interests.
